A multicenter, randomized, double-blind, Phase III trial to evaluate the safety, immunogenicity, and efficacy of MSB11022 compared with Humira® in patients with moderately to severely active rheumatoid arthritis
Latest Information Update: 06 Jul 2023
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Registrational
- Acronyms AURIEL-RA
- Sponsors Fresenius Kabi; Merck KGaA
- 15 Jun 2019 Safety and efficacy results (n=288) presented at the 20th Annual Congress of the European League Against Rheumatism.
- 09 Nov 2018 Status changed from active, no longer recruiting to completed.
- 30 Jul 2018 Planned End Date changed from 7 Aug 2018 to 30 Aug 2018.